Company news

Moleculin Biotech, Inc. news in 2023

Moleculin Biotech, Inc.'s news releases, calls and decks from 2023, newest first.

View company

Moleculin Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market

December 19, 2023

Moleculin Presents Positive Interim Data from Phase 1B/2 Clinical Trial in AML at Meeting with KOL's in Conjunction with ASH Annual Meeting

December 10, 2023

Moleculin Reports Third Quarter 2023 Financial Results

November 12, 2023

Moleculin Announces Positive Interim Data in Annamycin Clinical Trials: MB-106 AML Trial Complete Response (CR) Rate of 38% and MB-107 STS Lung Mets Trial Median Phase 1B Extended Overall Survival of 11 Months

November 12, 2023

Moleculin to Report Third Quarter Financial Results on November 13, 2023 and Host Conference Call and Webcast

November 6, 2023

Moleculin Presents Positive Preliminary Efficacy Findings from Phase 1B/2 Clinical Trial Demonstrating 64% Stable Disease Rate Through Two Cycles of Annamycin for the Treatment of Soft Tissue Sarcomas (STS) Lung Metastases

November 5, 2023

Moleculin Doses First Subjects in Phase 2 Portion of Clinical Trial Evaluating Annamycin in Combination with Cytarabine (Ara-C) for the Treatment of Acute Myeloid Leukemia (AML)

October 1, 2023

Moleculin Announces Completion of Enrollment in U.S. Phase 1B/2 Clinical Trial Evaluating Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases (MB107)

September 20, 2023

Moleculin Announces New Positive Independent Report of No Cardiotoxicity in Annamycin

September 17, 2023

Moleculin Announces Abstract Accepted for Poster Presentation at the 2023 Connective Tissue Oncology Society (CTOS) Annual Meeting

September 13, 2023

Moleculin Reports Second Quarter 2023 Financial Results

August 10, 2023

Moleculin Provides Update on Ongoing Clinical Trials and Outlines Expected Upcoming Milestones

August 9, 2023

Moleculin to Report Second Quarter Financial Results on August 11, 2023 and Host Conference Call and Webcast

August 2, 2023

Moleculin Announces Publication of Data from Successful European Phase 1 Trial Evaluating Annamycin as Single Agent Treatment of Relapsed or Refractory Acute Myeloid Leukemia (AML)

July 12, 2023

Moleculin Announces Adjournment of 2023 Annual Meeting to June 15, 2023

May 29, 2023

Moleculin Reports First Quarter 2023 Financial Results

May 10, 2023

Moleculin to Report First Quarter Financial Results on May 11, 2023 and Host Conference Call and Webcast

May 3, 2023

Moleculin Successfully Completes First Cohort in Phase 1b/2 Trial Evaluating Annamycin in Combination with Cytarabine (Ara-C) for the Treatment of Acute Myeloid Leukemia (AML)

May 1, 2023

Moleculin Announces Presentation of Positive Pharmacokinetics and Tissue-Organ Distribution Data Demonstrating High Antitumor Activity of Annamycin in Preclinical Cancer Models

April 17, 2023

Moleculin Reports Full Year 2022 Financial Results and Provides Pipeline Update

March 22, 2023

Moleculin Announces Interim Phase 2 Data in STS Clinical Trial and Update on Recruiting, Preliminary Efficacy and Expected Milestones for AML Clinical Trials

March 21, 2023

Moleculin Announces Acceptance of Abstract to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2023

March 20, 2023

Moleculin to Report Full Year 2022 Financial Results on March 22, 2023 and Host Conference Call and Webcast

March 14, 2023

Moleculin Announces it Has No Exposure to Silicon Valley Bank Situation

March 12, 2023

Moleculin Announces Publication of Data Supporting Development of Non-Cardiotoxic Anthracycline for the Treatment of Cancer in Peer-Reviewed European Journal of Cancer

March 8, 2023

Moleculin Announces Dosing of First Subject in Italy for Phase 1/2 Trial Evaluating Annamycin in Combination with Cytarabine (Ara-C) for the Treatment of Acute Myeloid Leukemia (AML)

February 28, 2023

Moleculin Announces Final Topline Data from Successful European Phase 1 Trial Evaluating Annamycin as Single Agent Treatment of Relapsed or Refractory Acute Myeloid Leukemia (AML)

February 12, 2023

Calls in 2023

Decks in 2023